IPX · IperionX Limited

Current Thesis

IperionX's domestic-titanium recovery thesis has failed its published price test: the 2026-09-18 weekly close of $20.85 breached the $21.66 invalidation threshold retained in the September 5 research. That outcome remains recorded despite fresh technical evidence; the threshold is not moved lower.

The company reported GenX continuous-production results on 2026-09-16 covering more than 500 kilograms across four runs totaling 41 hours. These are company-reported measurements, not evidence of sustained commercial profitability. September 16 filing

The inference remains that the narrative is dead as a price structure — the September 18 close breached the published threshold despite the August 31 Army award and September 16 technical announcement. The underlying industrial proposition remains domestic titanium manufacturing supported by government contracts; its commercial outcome is unresolved.

Bullish and bearish views on IperionX Limited

The model's bull view on IperionX Limited (IPX), in brief: Measured processing gains support development. The bear view: Validation remains a small sample. The 2026-09-16 assessment excluded an angular-powder sample from an interrupted furnace run. Four production runs are too small a sample to establish sustained reliability or commercial margins. Validation methodology Revenue evidence remains… Both cases follow in full.

Bull Case

• Measured processing gains support development. The 2026-09-16 release reported six times the throughput over comparable runtime and more than 75% lower power consumption per kilogram against the company's batch process. Sustained production economics remain unproven. GenX results
• Army funding has contractual substance. IperionX's 2026-08-31 announcement specified US$11.5 million funded and obligated under Task Order 2, against a stated US$18.5 million base value. The US$6.9 million of additional options were unexercised and unfunded; the maximum award is not equivalent to cash received.
• Government reimbursements supplement equity funding. The June quarterly report dated 2026-07-30 disclosed US$37.1 million of remaining obligated reimbursable government funding. That supports eligible expenditure, rather than establishing customer demand.

Bear Case

• Validation remains a small sample. The 2026-09-16 assessment excluded an angular-powder sample from an interrupted furnace run. Four production runs are too small a sample to establish sustained reliability or commercial margins. Validation methodology
• Revenue evidence remains incomplete. The 2026-07-30 June quarterly disclosed no customer revenue figure and reported US$11.9 million of operating cash outflow for the quarter. Missing revenue disclosure does not establish zero revenue, but it prevents a quantified commercial-conversion claim.
• Project funding remains separate. The 2026-06-04 Titan feasibility study specified US$381.3 million of development capital expenditure. The approximately US$84 million pro-forma cash disclosed on 2026-07-30 was a historical financing presentation, not a September cash balance or evidence that Titan was fully financed.

Setup & Price Structure

The adjusted daily-bar series records a 2026-09-18 close of $20.85, a three-month decline of 31.4%, and a price 65.3% below the series' $60.11 trailing-year high. The 14-day relative strength index was 49.3. These observations do not establish a base or renewed participation.

The September 18 close was below both the published $21.66 threshold and the US$21.98 July placement price. The latter is a public financing reference, not demonstrated support.

The observable supply event remains the US$50 million American depositary share offering priced at US$21.98 in July 2026. Jefferies' September 2 initiation carried a US$26 analyst target, but analyst coverage is not positioning data. No dated short-interest series, fund-flow series or current moving-average measurements establish crowding in this refresh.

Catalyst Calendar (next 30 days)

• ~2026-09-23, estimated full-year results. MarketBeat lists this date using historical reporting schedules and explicitly says the company has not confirmed it. The statements could establish reported customer revenue and annual cash consumption; the estimated date itself is not a company commitment. Earnings calendar
• 2026-09-30, annual financial-document deadline. ASX Listing Rule 4.5.1 requires the applicable annual documents within three months of the accounting-period end. This is the filing deadline retained for the June year-end, not a confirmed earnings-call date or a promised redomiciliation update. ASX periodic-disclosure rules

What Would Change Our Mind

The loss of the published downside threshold has already broken the recovery structure: a weekly close below $21.66 occurred on 2026-09-18 at $20.85. A later rebound cannot reverse that recorded outcome.

A replacement recovery case would require both disclosed customer receipts and a weekly close above the July 2026 placement reference of $21.98. Its price confirmation would fail on a subsequent weekly close below $21.98. Those conditions are prospective tests, not findings that a new base exists.

The company's September 16 release schedules further GenX integration and engineering work during the fourth quarter of 2026, without an exact completion date. Disclosure that integration was postponed beyond that quarter would contradict that timetable. Development schedule

Correlation Notes

The August 31 Army award establishes a company-specific connection to defense manufacturing; the June 4 Titan study establishes exposure to critical-mineral project development. Neither document establishes share-price correlation with defense contractors or rare-earth producers. No matched return series is available here to measure those relationships, so this remains a single-name setup rather than evidence of a confirmed group move.